First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 861 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Low-Dose Aspirin Could be an Alternative to Colectomy for Preventing Colorectal... April 8, 2021 First Prospective Description of Familial EGFR-mutated Lung Cancer August 23, 2023 ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ February 7, 2019 Darolutamide Delays the Spread of Some Prostate Cancers March 15, 2019 Load more HOT NEWS ¿Ahora qué? 10 maneras de adaptarse a la vida cotidiana después... EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab New Drugs, New Side Effects: Complications of Cancer Immunotherapy Silence Speaks Volumes
